Direct antiviral agents in hepatitis C virus related liver disease: Don’t count the chickens before they’re hatched

Stella Compagnoni, Erica Maria Bruno, Giorgio Madonia, Marco Cannizzaro, Salvatore Madonia

Abstract

Since molecules with direct-acting antiviral (DAA) became available, the landscape of the treatment of hepatitis C virus (HCV) infection has completely changed. The new drugs are extremely effective in eradicating infection, and treatment is very well tolerated with a duration of 8-12 wk. This review aims to report the outstanding clinical benefits of DAA and to highlight their critical disadvantages, identifying some clinically relevant hot topics. First, do the rates of virological response remain as high when patients with more advanced cirrhosis are considered? Large studies have shown slightly lower but still satisfactory rates of response in these patients. Nevertheless, modified schedules with an extended treatment duration and use of ribavirin may be necessary. Second, does the treatment of HCV infection affect the risk of occurrence and recurrence of liver cancer? Incidence is reduced after viral eradication but remains high enough to warrant periodic surveillance for an early diagnosis. In contrast, the risk of recurrence seems to be unaffected by viral clearance; however, DAA treatment improves survival because of the reduced risk of progression of liver disease. Third, can HCV treatment also have favorable effects on major comorbidities? HCV eradication is associated with a reduced incidence of diabetes, an improvement in glycemic control and a decreased risk of cardiovascular events; nevertheless, a risk of hypoglycemia during DAA treatment has been reported. Finally, is it safe to treat patients with HCV/ hepatitis B virus (HBV) coinfection? In this setting, HCV is usually the main driver of viral activity, while HBV replication is suppressed. Because various studies have described HBV reactivation after HCV clearance, a baseline evaluation for HBV coinfection and a
INTRODUCTION

Hepatitis C virus (HCV) infection is a major cause of chronic liver disease, with more than 70 million people infected all over the world[1]. HCV is responsible for many cases of hepatitis, liver cirrhosis, liver cancer (hepatocellular carcinoma, HCC), transplantation (orthotopic liver transplantation, OLT) and liver-related deaths. Initially, all the available treatments were interferon (IFN)-based. However, they were unsatisfactory mainly because the rates of viral response were between 30% and 50%, and their efficacy was strongly dependent on viral genotype and the degree of liver fibrosis. Furthermore, IFN-based treatments had a long duration of 24-48 wk and marked adverse effects limited their use in patients with advanced liver disease and major comorbidities.

More recently, IFN-free treatments with direct-acting antiviral (DAAs) drugs were registered. Their availability has substantially changed the HCV-infection setting. Indeed, DAAs are able to obtain rates of sustained virological response (SVR) higher than 95%, independently of virus genotype or degree of liver damage. They have short duration schedules of 8 wk to 12 wk and are extremely well tolerated[2-4]. More recently, the advent of pangenotypic DAAs has further extended and simplified their use[2,5].

The effects of viral clearance in patients with chronic hepatitis are well known. SVR is generally associated with a biochemical response (normalization of liver enzymes), improvement of liver necroinflammation and reduction in fibrosis progression or regression of fibrosis[6,7].

Due to their efficacy in advanced fibrosis and high tolerability, DAA use has been extended to patients with advanced and even decompensated cirrhosis and patients with severe comorbidities, raising new questions. What benefits can be expected from eradicating HCV in patients who already have advanced liver disease? Is DAA-induced SVR associated with an appreciable benefit in liver cancer? Can HCV treatment have favorable effects on major concomitant disorders such as diabetes or cardiovascular disease? Is there any cause for concern when using DAAs in HCV patients with a concomitant hepatitis B virus infection?
WHAT BENEFITS CAN BE EXPECTED FROM ERADICATING HCV IN PATIENTS WHO ALREADY HAVE ADVANCED LIVER DISEASE?

The new-generation DAA regimens sofosbuvir/velpatasvir and glecaprevir/pibrentasvir have shown rates of SVR higher than 95% in patients with cirrhosis, independent of genotype. No concerns about their safety have been described[2,5,8]. Notably, these results have been confirmed in real-world studies conducted in large and heterogeneous populations, including patients with intravenous drug use, patients with advanced chronic kidney disease or those aged over 70, who are usually excluded from registrational trials[9,10].

Previous studies demonstrated the favorable effects of viral eradication on the histopathological features of cirrhosis, showing that SVR is associated with a histological decrease in fibrosis or cirrhosis regression[11]. More recently, various studies have shown the clinical advantages of treating HCV infection in patients with cirrhosis. One study analyzed a large French cohort of 1323 patients with biopsy-proven cirrhosis, showing that SVR was significantly associated with reductions in the risk of decompensation and of both overall and liver-related mortality[12]. The association between SVR and reduction in mortality for all causes was confirmed by another French study including 9895 cirrhotic patients followed up for more than 33 mo[6].

Another large cohort study from the United States evaluated the impact of DAA-induced SVR on all-cause mortality in 15059 HCV patients with advanced liver disease. SVR was independently associated with a reduced risk of death compared to no SVR (hazard ratio: 0.26; 95% confidence interval: 0.22-0.31; P < 0.001)[13].

Studies on hemodynamics have examined the relationship between SVR and portal hypertension. A reduction in the hepatic venous pressure gradient (HVPG) has been reported after SVR with DAA, leading to a reduced risk of hepatic decompensation[14].

Are such relevant results confirmed when patients with more advanced/decompensated cirrhosis are considered?

DAs have been used in patients with Child-Pugh B and C cirrhosis who were unsuitable for treatment with IFN-based regimens. Although such patients remain harder to treat and protease inhibitors are contraindicated in this setting, various studies have reported SVR rates higher than 90% after adding ribavirin or prolonging treatment to 24 wk[15-17].

Even in patients with advanced cirrhosis, virological response is associated with a clinical benefit. Model for end-stage liver disease score and liver function improve in one third to one half of treated patients. Furthermore, treatment is well tolerated with no safety concerns[18].

Hepatic venous pressure gradient reduction after SVR has been observed even in Child-Pugh class B cirrhosis[19], but the benefits for portal pressure can be reduced in patients with more advanced liver cirrhosis. In a multicenter prospective study, although a significant reduction in hepatic vein pressure gradient was observed after SVR, this reduction was only marginal in patients who had higher, clinically significant portal hypertension at baseline[20].

Strong evidence of the clinical impact of DAs in these patients can be found in the setting of OLT. HCV-related liver disease has been the most common indication for OLT in Western Europe for the last 20 years. DAA introduction has significantly contributed to change the OLT scenario, greatly decreasing the burden of HCV disease at waiting list registration. Data from an Italian cohort showed that after the extended approval of DAA therapies was granted in Italy in 2014, waiting list registrations for OLT due to HCV-related disease decreased from 43.3% of all waiting list registrations in the pre-DAA period to 37.2%[21].

Data from the European liver transplantation cohort showed that treatment with DAs allowed as many as one third of patients already on waiting list to be delisted because of clinical improvement, with a very low risk of a subsequent need for relisting[22].

High rates of SVR have also been demonstrated in patients treated after transplantation[23]. A study from Spain conducted in 112 OLT recipients showed SVR to be associated with liver fibrosis regression and a significant improvement in liver function and survival[7].

In conclusion, DAA treatment allows high rates of SVR even in patients with advanced cirrhosis. These patients remain difficult to treat, are not suitable for protease inhibitors and may require treatment prolongation and ribavirin use. SVR is associated with an improvement in liver function and a reduction in portal pressure in a large proportion of patients. DAA availability has reduced the burden of HCV-
related disease in the liver transplantation setting (Table 1).

**IS DAA-INDUCED SVR ASSOCIATED WITH AN APPRECIABLE BENEFIT IN HCC?**

A number of studies have evaluated the role of DAA-induced SVR in both the occurrence and recurrence of HCC. Overall, SVR obtained with DAA is associated with a 70% incidence reduction[24].

A retrospective cohort study on a large population from the United States evaluated the annual rates of HCC in HCV patients treated with DAA, comparing those who achieved SVR to those who did not. The study included 22500 patients treated with DAA; about one third of them had cirrhosis. SVR was achieved in 19518 but not in 2982. The highest risk of HCC was reported in cirrhotic patients. Even though SVR significantly reduced the risk of HCC, the absolute risk of HCC remained high in patients with cirrhosis despite SVR. Thus, patients with cirrhosis should be kept under long-term surveillance for HCC[25].

Another real-world study from Italy, including a cohort of more than 2000 cirrhotic patients, showed a significant reduction in HCC risk after achieving SVR in patients with Child-Pugh class A and class B disease. Nevertheless, the mean time lapse between exposure to DAAs and HCC occurrence was 9.8 mo, with no significant difference between patients with SVR and those without; this observation would suggest that the high incidence of HCC described in the first year after DAA might be largely related to the presence of previously unrecognized HCC cases. Thus, previously unrecognized HCC could largely contribute to an overestimation of the early risk of HCC after DAAs[24,26]. In this study, albumin levels and platelet counts, associated with liver function and portal hypertension, respectively, were identified as significant predictors of HCC occurrence.

More recently, similar results have been confirmed in long-term follow-up studies. A retrospective study from East Asia, involving a large cohort of 5814 HCV patients treated with DAA and followed up for a median of 2.9 years, reported a significant reduction in HCC risk in SVR patients compared with those without SVR[27].

Another retrospective study was recently conducted in 129 Veterans Health Administration hospitals. Results confirmed that in cirrhotic patients successfully treated with DAA, the occurrence of HCC was reduced but remained high enough to warrant long-term HCC surveillance. Interestingly, the risk of HCC remained stable over the 3 year observation period[28].

Several studies have evaluated the risk of HCC recurrence in DAA-treated HCV patients on HCC remission at DAA initiation. Some early studies raised concerns about an increased risk of HCC recurrence in patients treated with DAAs compared with those receiving IFN. Furthermore, other studies hypothesized that the rapid clearance of HCV during DAAs could decrease the immune surveillance of small HCC clones, increasing the risk of early HCC recurrence[29].

A meta-analysis published in 2017 compared the risk of HCC recurrence in patients treated with DAA or IFN-based treatments, finding no difference between the two groups. In particular, DAA treatment was not associated with a higher HCC recurrence[30]. More recently, a retrospective, population-based cohort study including 17836 patients confirmed that neither the HCC incidence rate nor HCC-free survival were significantly different in the DAA group compared to the IFN group[31].

A large retrospective cohort study from the United States and Canada found no significant differences in either overall or early HCC recurrence between patients who received DAAs and patients not receiving therapy after a complete response to HCC treatment[32]. Even if the risk of HCC recurrence appears not to be affected by curative DAA treatment, a reduction in the risk of decompensation of cirrhosis has been observed in these patients, and overall survival appears to be improved in those achieving SVR[33].

A retrospective cohort study from the United States and Canada, including 797 patients with previous HCV-related HCC who had achieved a complete HCC response at treatment initiation, confirmed that SVR after DAA treatment was associated with a significant reduction in the overall risk of death[34]. A history of previous HCC recurrence and previous main tumor size appear to be related with the risk of recurrence[35].

In conclusion, the available data show that HCC incidence is reduced in DAA-treated patients. The risk of HCC recurrence appears unaffected, but overall survival can be increased in these patients because of the reduced risk of decompensation. The
Table 1 Benefits and pitfalls of sustained virological response using direct-acting antivirals in different hepatitis C virus scenarios

| Setting                      | Benefits                                                                 | Pitfalls                                                                 |
|------------------------------|---------------------------------------------------------------------------|--------------------------------------------------------------------------|
| Advanced liver disease       | SVR rates higher than 95%; Reduced risk of decompensation and death      | Nothing to report                                                        |
|                              | HVPG reduction                                                           |                                                                          |
| Decompensated cirrhosis      | Liver function improvement in one third to one half of patients; Treatment well-tolerated | Slightly lower SVR rates; Need for ribavirin or treatment elongation to 24 wk |
| HCC occurrence               | Reduced occurrence of HCC                                                | Still relevant risk of HCC; Need for periodic surveillance for early diagnosis |
| HCC recurrence               | Improved survival due to reduced risk of decompensation                  | Risk of HCC recurrence unaffected by SVR; Need for periodic surveillance for early diagnosis |
| Diabetes                     | Reduced incidence of diabetes; Improvement of glycemic control           | Risk of hypoglycemia in patients receiving antidiabetic medications; Adjustments of antidiabetic medication may be necessary |
| Cardiovascular diseases      | Decreased risk of cardiovascular events; Reduction in cardiovascular deaths | Nothing to report                                                        |
| HBV coinfection              | As for general HCV population                                            | Risk for HBV reactivation; Pre-DAA screening for HBV indicated; Need for HBV treatment or on-treatment HBV monitoring as requested |

DAA: Direct-acting antiviral; HBV: Hepatitis B virus; HCC: Hepatocellular carcinoma; HCV: Hepatitis C virus; HVPG: Hepatic venous pressure gradient; SVR: Sustained virological response.

An interesting, albeit unsolved issue regarding the association between HCV infection and glucose abnormalities [insulin resistance (IR) and type 2 diabetes mellitus (T2DM)]. Even though the mechanisms that lead to the development of IR and T2DM in predisposed HCV-infected patients are not fully understood, HCV seems to play a direct role by interfering with glucose metabolism. As indicated by many studies, HCV-infected subjects have a significantly higher risk of T2DM than noninfected controls[36,37], HCV-cleared patients[38] and HBV-infected patients[39]. Moreover, some data suggest that the higher risk might be independent of body mass index and family history[40], strengthening the hypothesis of HCV as a direct cause of T2DM.

Although it is quite clear that HCV infection increases the risk of developing T2DM, the data regarding whether the stage of liver disease could affect the development of T2DM are ambiguous. Indeed, some studies show that HCV-related cirrhosis (and in particular decompensated cirrhosis) is associated with a higher risk of DM than in non-HCV cirrhosis, HCV-cleared patients and chronic HCV-infections[38]. Due to this close association between HCV infection and the development of T2DM, many studies have evaluated whether glucose abnormalities could on the contrary affect the natural course of HCV infection.

To our knowledge, DM and IR are associated with a worse outcome in patients with chronic hepatitis C, with an increased risk of developing liver cirrhosis and decompensation over time[41]. In particular, the effects of fasting glucose levels seem to be increased in genotype 1 and genotype 2 patients[42].

In a cohort study, baseline diabetes was independently associated with a higher prevalence of ascites, bacterial infections and encephalopathy detected at inclusion and was independently associated with the development of ascites, renal dysfunction, bacterial infections and HCC during follow-up, showing T2DM as an independent prognostic factor in patients with chronic hepatitis C and cirrhosis. Transplantation-free survival was also shortened, independent of the baseline model for end-stage liver disease score[43]. Furthermore, some data suggest an important role for new-onset diabetes in chronic hepatitis C patients, which seems to lead to a significantly higher cumulative incidence of HCC[37,44].

The effects of HCV eradication on glycometabolic control have been widely investigated. Although SVR after IFN/ribavirin therapies was already known to be risk of both the incidence and recurrence of DAA remains high enough to warrant long-term surveillance after treatment, even in patients with SVR (Table 1).
associated with a significantly reduced risk of developing T2DM after long-term follow-up[45-48], data collected in the DAA era suggest a great benefit of antiviral treatment in HCV patients who already have glucose abnormalities. Many studies have shown a significant improvement in insulin sensitivity[49], hemoglobin A1c and fasting glucose plasma levels in patients who achieved SVR after DAA therapy[50-53]. A prospective case-control study showed IR improvements in 76.5% of patients who achieved SVR and a normalized IR in about 41% of them, with these data being confirmed 3 mo after treatment withdrawal[54]. Moreover, patients with SVR also required a lower dose of antidiabetic medications than those without[51]. Interestingly, these metabolic changes seem to be body mass index-independent[55]. Nevertheless, more studies are needed to clarify the long-term effects after DAA therapy.

All these observations lead to another question: Does HCV eradication affect diabetes mellitus-related long-term complications? The clinical impact of successful antiviral therapy on the long-term outcomes of T2DM in HCV patients remains largely unknown, mainly because of the lack of specific prospective studies. However, based on the above-mentioned data, it is reasonable to presume that HCV eradication could also reduce long-term metabolic-related complications. A Taiwanese population-based cohort study found that better renal and cardiovascular outcomes were obtained in the group treated with the antiviral IFN/ribavirin regimen than in the untreated cohort[56]. Another study showed a decreased incidence of acute coronary syndrome, end-stage renal disease, ischemic stroke and retinopathy after HCV eradication, both with IFN and with DAA treatment, regardless of cirrhosis[57]. Whether the reduction in cardiovascular events observed in diabetic patients after HCV eradication is due to a beneficial effect on T2DM itself or to the disappearance of systemic chronic inflammation remains to be clarified.

Although HCV eradication has important benefits for glycometabolic control, some negative aspects of DAA treatment in diabetic patients must be considered. In fact, a Health Canada review has pointed out a link between DAA use and the risk of dysglycemia (including hypo/hyperglycemia and new-onset diabetes). The evidence was stronger concerning the risk of hypoglycemia in patients with an increased insulin sensitivity and a decreased need for antidiabetic medications[58]. Thus, patients with diabetes who start an anti-HCV therapy with DAAs should be closely monitored for changes in glucose levels, particularly in the first 3 mo of treatment, and adjustments to their diabetic medication or doses may be necessary.

Independent of the association between HCV and diabetes and diabetes-related consequences, HCV infection seems to be directly associated with an increased risk of cardiovascular disease. Emerging data show that HCV infection might increase the risk of cardiovascular disease by 20%. HCV RNA has been found in the carotid plaques of infected subjects[60]. Thus, HCV could cause atherosclerosis through colonization and replication within the arterial wall[61], but other mechanisms may be involved, such as oxidative stress and the imbalanced secretion of inflammatory molecules[62-65], including C-reactive protein, soluble adhesion molecules and soluble E-selectin[66].

Does SVR have a favorable impact on major adverse cardiovascular events? It has been demonstrated that HCV clearance improves carotid atherosclerosis. Indeed, an intima-media thickness ≥ 1 mm has been associated with a higher risk of cardiovascular events[67,68], but when evaluated at 9-12 mo after the end of DAA-therapy, intima-media thickness and carotid thickening appeared significantly decreased compared to baseline.

An analysis of a large cohort of HCV-infected veterans evaluated the impact of HCV treatment on cardiovascular events in a population free of any cardiovascular disease at baseline. The study included 4436 patients treated with a pegylated interferon-ribavirin regimen, 12667 patients treated with a DAA regimen and 17103 HCV-infected matched controls. Results showed that HCV treatment both with IFN-based regimens and with DAAs was associated with a significantly decreased incidence of all cardiovascular events: Acute myocardial infarction, unstable angina, congestive heart failure, peripheral vascular disease, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting and stroke. The greatest benefits were observed in the DAA-treated group. Patients with advanced liver fibrosis at baseline had a higher incidence of cardiovascular events than those with minimal or no fibrosis. Nevertheless, a marked reduction in cardiovascular disease incidence was observed in treated patients independently of the degree of liver fibrosis, and patients with more advanced fibrosis received the greatest advantage[69].
A reduction in cardiovascular deaths after viral eradication has been observed in cirrhotic patients[70]. Moreover, a recent evaluation of the Italian Rete Sicilia Selezione Terapia-HCV cohort confirmed that DAA-induced SVR is independently associated with a reduction in the risk of both hepatic and cardiovascular mortality[71,72]. This observation has been further confirmed in other studies[73].

In conclusion, DAA treatment in HCV patients with glucose abnormalities is associated with an improvement in glucose control and a reduced need for antidiabetic medications. Furthermore, HCV eradication in diabetic patients seems to reduce the incidence of long-term vascular complications. However, glucose levels in HCV diabetic patients undergoing DAA treatment should be closely monitored because of the risk of hypoglycemia, and diabetic medications may need some adjustment.

DAA treatment is associated with a significantly decreased incidence of all cardiovascular events independent of the degree of liver fibrosis and is also associated with a reduction in the risk of both hepatic and cardiovascular mortality (Table 1).

IS THERE ANY CAUSE FOR CONCERN WHEN USING DAAs IN HCV PATIENTS WITH A CONCOMITANT HBV INFECTION?

In patients with a HCV-HBV coinfection, HCV is usually the main driver of chronic inflammation and viral activity, while HBV DNA levels are generally low or undetectable[1]. In these patients, HBV flares have been described after HCV suppression both by IFN-based treatments and by DAAs[74,75].

In 2016, the Food and Drugs Administration issued an alert about the risk of HBV reactivation in patients treated with DAAs. Notably, in some cases HBV reactivation resulted in severe liver disorders or death. The full data were subsequently published. They referred to 29 cases of HBV reactivation in HCV-HBV patients after treatment with DAs. The median time lapse between DAA initiation and HBV reactivation was 46 d. Before DAA initiation, 13 patients were hepatitis B surface antigen (HBsAg) positive, 4 patients were HBsAg negative, and 12 patients did not have HBsAg reported. Two cases resulted in death and one case in liver transplantation[76,77].

Since then, various reports have been published on HBV reactivation in HCV-HBV patients treated with DAAs, both in HBsAg positive and in HBsAg negative/anti-hepatitis B core (HBc) positive patients[75,78,79]. The risk of HBV reactivation is lower in HBsAg negative/anti-HBc positive than in HBsAg-positive patients. An asymptomatic increase in HBV DNA level is generally observed, although clinically relevant events are infrequent[80].

On the basis of all these data, the European Association for the Study of the Liver guidelines state that patients undergoing DAA treatment for hepatitis C should be tested for HBs antigen, anti-HBc antibodies and anti-HBs antibodies. If HBsAg is present, then therapy with anti-HBV nucleoside/nucleotide analogue is indicated. In HBsAg negative/anti-HBc positive patients, monitoring for alanine transaminase levels, HBsAg and HBV DNA would be warranted during and after anti-HCV therapy[1].

In conclusion, patients with HCV/HBV coinfection there is a risk of HBV reactivation after HCV clearance. However, the risk is low, particularly in HBsAg-negative/anti-HBc-positive patients. It is generally associated with an asymptomatic increase in HBV DNA levels, but threatening clinical events have been described. Patients undergoing DAA treatment should be tested for HBV infection (Table 1).

CONCLUSION

DAAs are extremely effective in eradicating infection. Furthermore, treatments are very well-tolerated, and their duration is reduced. Most of the information has been obtained from studies including patients with chronic hepatitis or early cirrhosis, whereas large studies in patients with advanced cirrhosis have shown slightly lower but still quite satisfactory response rates, although modified treatment schedules may be necessary.

Despite these enthusiastic results, some important points must be kept in mind. First, although the incidence of liver cancer is reduced after viral eradication, it remains high enough to warrant the continuation of periodic surveillance for an early diagnosis. The risk of recurrence seems to be unaffected, even if survival improves in treated patients because of the reduced risk of liver disease progression.
Furthermore, HCV eradication is associated with a reduced diabetes incidence and improved glycemic control, but there are concerns about the risk of hypoglycemia after virus clearance.

In patients with HCV/HBV coinfection, HBV reactivation after HCV clearance has been described, sometimes associated with clinically relevant events. Baseline evaluation for HBV coinfection is therefore mandatory before treatment.

REFERENCES

1. European Association for the Study of the Liver. EASL recommendations on treatment of hepatitis C: Final update of the series®. J Hepatol 2020; 73: 1170-1218 [PMID: 32956768 DOI: 10.1016/j.jhep.2020.08.018]

2. Feld JJ, Jacobson IM, Hézodé C, Asselah T, Ruane PJ, Gruener N, Abergel A, Mangia A, Lai CL, Chan HL, Mazzotta F, Moreno C, Yoshida E, Shafran SD, Towner WJ, Tran TT, McNally J, Osinius A, Svarovskaia E, Zhu Y, Brandin DM, McHutchison JG, Agarwal K, Zeuzem S; ASTRAL-1 Investigators. Sofosbuvir and Velpatasvir for HCV Genotype 1, 2, 4, 5, and 6 Infection. N Engl J Med 2015; 373: 2599-2607 [PMID: 26571066 DOI: 10.1056/NEJMoa1512610]

3. Foster GR, Afdhal N, Roberts SK, Bräu N, Gane EJ, Pianko S, Lawitz E, Thompson A, Shiffman ML, Cooper C, Towner WJ, Conway B, Ruane P, Bourlière M, Asselah T, Berg T, Zeuzem S, Rosenberg W, Agarwal K, Stedman CA, Mo H, Dvory-Sobol H, Han L, Wang J, McNally J, Osinius A, Brandrin DM, McHutchison JG, Mazzotta F, Tran TT, Gordon SC, Patel K, Reau N, Mangia A, Sulkowski M; ASTRAL-2 Investigators. Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 Infection. N Engl J Med 2015; 373: 2608-2617 [PMID: 26575258 DOI: 10.1056/NEJMoa1512612]

4. Foster GR, Gane E, Asatryan A, Asselah T, Ruane PJ, PolS, Poordad F, Stedman CA, Dore G, Roberts SK, Kaita K, Vierling J, Vargas HE, Kort J, Lin C-W, Liu R, NgT, Mensa F. ENDURANCE-3: safety and efficacy of glecaprevir/pibrentasvir compared to sofosbuvir plus daclatasvir in treatment-naive HCV genotype 3-infected patients without cirrhosis. J Hepatol 2017; 66: S33 [DOI: 10.1016/S0168-8278(17)30324-4]

5. Forns X, Lee SS, Valdes J, Lens S, Ghalib R, Aguilar H, Felizarta F, Hassanein T, Hinrichsen H, Rincon D, Morillas R, Zeuzem S, Homsyans M, Nelson DR, Yu Y, Krishnan P, Lin CW, Kort JJ, Mensa FJ. Glecaprevir plus pibrentasvir for chronic hepatitis C virus genotype 1, 2, 4, 5, or 6 infection in adults with compensated cirrhosis (EXPEDITION-1): a single-arm, open-label, multicentre phase 3 trial. Lancet Infect Dis 2017; 17: 1062-1068 [PMID: 28818546 DOI: 10.1016/S1473-3099(17)30496-6]

6. Carrat F, Fontaine H, Dorival C, Simony M, Diallo A, Hézode C, De Ledingen V, Laraey D, Haour G, Bronowicki JP, Zoulim F, Asselah T, Marcellin P, Thabut D, Leroy V, Tran A, Habersetzer F, Samuel D, Guyader D, Chazouillères O, Mathurin P, Metivier S, Alric L, Riachi G, Gournay J, Weilert F, Lee SS, Valdes J, Lens S, Ghalib R, Aguilar H, Felizarta F, Hassanein T, Hinrichsen H, Rincon D, Morillas R, Zeuzem S, Homsyans M, Nelson DR, Yu Y, Krishnan P, Lin CW, Kort JJ, Mensa FJ. Glecaprevir/pibrentasvir compared to sofosbuvir plus daclatasvir in treatment-naive HCV genotype 3 infected patients without cirrhosis. J Hepatol 2017; 66: S33 [DOI: 10.1016/S0168-8278(17)30324-4]

7. Mauro E, Crespo G, Montironi C, Londoño MC, Hernández-Gea V, Ruiz P, Sastre L, Lombardo J, Maríñez Z, Díaz A, Colmenero J, Rínola A, García-Pagán JC, Brunet M, Forns X, Navasa M. Portal pressure and liver stiffness measurements in the prediction of fibrosis regression after sustained virological response in recurrent hepatitis C. Hepatology 2018; 67: 1683-1694 [PMID: 28960366 DOI: 10.1002/hep.29577]

8. Wyles D, Poordad F, Wang S, Abic L, Felizarta F, Kwo PY, Maliakkal B, Agarwal K, Hassanein T, Weichert F, Lee SS, Kort J, Lovell SS, Liu R, Lin CW, Pilot-Matias T, Krishnan P, Mensa FJ. Glecaprevir/pibrentasvir for hepatitis C virus genotype 3 patients with cirrhosis and/or prior treatment experience: A partially randomized phase 3 clinical trial. Hepatology 2018; 67: 514-523 [PMID: 28929612 DOI: 10.1002/hep.29541]

9. Mangia A, Milligan S, Khalili M, Fagioli S, Shafran S, Carrat F, Ouzan D, Papaetheodoridis G, Ramji A, Borgia S, Wedemeyer H, Piazolla V, Hernández F, Wick N, Fishbein D, Lampertico P, Doucette K, Mertens M, Vanstraalen K, Turnés J. GS-03-Global real world evidence of sofosbuvir/velpatasvir as a simple, effective regimen for the treatment of chronic hepatitis C patients: Integrated analysis of 12 clinical practice cohorts”. J Hepatol 2019; 70: e2-e3 [DOI: 10.1016/S0168-8278(19)30003-9]

10. Lampertico P, Carrión JA, Curry M, Turnes J, Comberg M, Negro F, Brown A, Persico M, Wick N, Porcella A, Pangerl A, Crown E, Larsen L, Yu Y, Wedemeyer H. Real-world effectiveness and safety of glecaprevir/pibrentasvir for the treatment of patients with chronic HCV infection: A meta-analysis. J Hepatol 2020; 72: 1112-1121 [PMID: 32061651 DOI: 10.1016/j.jhep.2020.01.025]

11. D’Ambrosio R, Aghem A, Rumi MG, Ronchi G, Donato MF, Paradis V, Colombo M, Bedossa P. A morphometric and immunohistochemical study to assess the benefit of a sustained virological response in hepatitis C virus patients with cirrhosis. Hepatology 2012; 56: 532-543 [PMID: 22271347 DOI: 10.1002/hep.25966]
12 Nahon P, Bourcier V, Layese R, Audreau E, Cagnot C, Marcellin P, Guyader D, Fontaine H, Larrey D, De Lédéghen V, Ouzan D, Zoulim F, Roulot D, Tran A, Bronowicki JP, Zarki JP, Leroy V, Riachi G, Caleix P, Pérón JM, Alric L, Bourrière M, Mathurin P, Dharnray S, Blanc JF, Abergel A, Serfaty L, Mallet A, Grangé JD, Attali P, Bacq Y, Wartelle C, Dao T, Benhamou Y, Pilette C, Silvain C, Christidis C, Capron D, Bernard-Chabert B, Zouman D, Di Martino V, Thibault V, Salmon D, Ziol M, Sutton A, Pol S, Roudot-Thoraval F; ANRS CO12 CirVira Group. Eradication of Hepatitis C Virus Infection in Patients With Cirrhosis Reduces Risk of Liver and Non-Liver Complications. *Gastroenterology* 2017; 152: 142-156. e2 [PMID: 27641509 DOI: 10.1053.j.gastro.2016.09.009]

13 Racksus L, Belporio PS, Shahlaunian TA, Mole LA. Impact of Sustained Virologic Response with Direct-Antiviral Treatment on Mortality in Patients with Advanced Liver Disease. *Hepatology* 2019; 69: 487-497 [PMID: 28749564 DOI: 10.1002/hep.29408]

14 Mandoor M, Hernández-Gea V, Garcia-Pagán JC, Reiberger T. Noninvasive Diagnostics for Portal Hypertension: A Comprehensive Review. *Semin Liver Dis* 2020; 40: 240-255 [PMID: 32557480 DOI: 10.1055/s-0040-1708806]

15 Curry MP, O’Leary JG, Bzowej N, Muir AJ, Korenblat KM, Fenkel JM, Reddy KR, Lawitz E, Flamm SL, Schiano T, Teperman L, Fontana R, Schiff E, Fried M, Doehele B, An D, McNally J, Osinski A, Brainard DM, McHutchison JG, Brown RS Jr, Charlton M; ASTRAL-4 Investigators. Sofosbuvir and Velpatasvir for HCV in Patients with Decompensated Cirrhosis. *N Engl J Med* 2015; 373: 2618-2628 [PMID: 26569658 DOI: 10.1056/NEJMoa1512614]

16 Manns M, Samuel D, Gane EJ, Mutimer D, McCaughan G, Buti M, Prieto M, Calleja JL, Peck-Radosavljevic M, Müllhaupt B, Agarwal K, Yoshida EM, Colombo M, Rizzetto M, Digiacomo A, Dvory-Sobol H, Denning J, Arterburn S, Pang PS, Brainard D, McHutchison JG, Dufour JE, Van Vlierberge H, van Hook B, Forns X, SOLAR-2 investigators. Ledipasvir and sofosbuvir plus ribavirin in patients with genotype 1 or 4 hepatitis C virus infection and advanced liver disease: a multicentre, open-label, randomised, phase 2 trial. *Lancet Infect Dis* 2016; 16: 685-697 [PMID: 26907736 DOI: 10.1016/S1473-3099(16)00052-9]

17 Lu M, Wu KH, Li J, Moorman AC, Spradling PR, Teshale EH, Boscarino JA, Daida YG, Schmidt MA, Rupp LB, Zhang T, Trudeau S, Gordon SC. Adjuvant ribavirin and longer direct-acting antiviral treatment duration improve sustained virological response among hepatitis C patients at risk of treatment failure. *J Viral Hepat* 2019; 26: 1210-1217 [PMID: 31197910 DOI: 10.1111/jvh.13162]

18 Foster GR, Irving WL, Cheung MC, Walker AJ, Hudson BE, Verma S, McLauchlan J, Mutimer DJ, Brown A, Gelson WT, MacDonald DC, Agarwal K; HCV Research, UK. Impact of direct antiviral therapy in patients with chronic hepatitis C and decompensated cirrhosis. *Hepatology* 2016; 64: 1224-1231 [PMID: 26829205 DOI: 10.1002/hep.2016.01.029]

19 Afdhal N, Everson GT, Calleja JL, McCaughan GW, Bosch J, Brainard DM, McHutchison JG, De-Oertel S, An D, Charlton M, Reddy KR, Asselah T, Gane E, Curry MP, Forns X. Effect of virological suppression on hepatic venous pressure gradient in hepatitis C patients with portal hypertension: A multicentre trial. *Hepatology Research* 2019; 49: 832-831 [PMID: 28295923 DOI: 10.1002/hepr.12706]

20 Luedtke S, Alvarado-Tapias E, Maritou Z, Londoño MC, Llop E, Martinez J, Ariza X, Baiges A, Gallego A, Bañares R, Puente A, Alibillos A, Calleja JL, Torres X, Hernández-Gea V, Bosch J, Villanueva C, Forns X, García-Pagán JC. Effects of All-Oral Anti-Viral Therapy on HVPG and Systemic Hemodynamics in Patients With Hepatitis C Virus-Cirrhosis-Associated Hypertension. *Gastroenterology* 2017; 153: 1273-1283.e1 [PMID: 28734831 DOI: 10.1053.j.gastro.2017.07.016]

21 Ferrarese A, Germani G, Gambotto M, Russo FP, Sensolo M, Zanetto A, Shalaby S, Cillo U, Zanus G, Angeli P, Burra P. Hepatitis C virus related cirrhosis decreased as indication to liver transplantation since the introduction of direct-acting antivirals: A single-center study. *World J Gastroenterol* 2018; 24: 4403-4411 [PMID: 30344424 DOI: 10.3748/wjg.v24.i38.4403]

22 Perricone G, Duvox C, Berenguer M, Cortesia P, Vinaixa F, Facchetti R, Mazzarelli C, Rockenschubr SR, Martini S, Morelli C, Monico S, Volpès R, Pageaux GP, Fagioullo S, Belli LS; European Liver and Intestine Transplant Association (ELITA). Delisting HCV-infected liver transplant candidates who improved after viral eradication: Outcome 2 years after delisting. *Liver Int* 2018; 38: 2170-2177 [PMID: 29750389 DOI: 10.10111/Liv.13878]

23 Poordad F, Schiff ER, Vierling JM, Landis C, Fontana RJ, Yang R, McPhee F, Hughes EA, Noviello S, Swenson ES. Daclatasvir with sofosbuvir and ribavirin for hepatitis C virus infection with advanced cirrhosis or post-liver transplantation recurrence. *Hepatology* 2016; 63: 1493-1505 [PMID: 26754432 DOI: 10.1002/hep.20446]

24 Singal AG, Lim JK, Kanwal F. AGA Clinical Practice Update on Interaction Between Oral Direct-Antiviral Antivirals for Chronic Hepatitis C Infection and Hepatocellular Carcinoma: Expert Review. *Gastroenterology* 2019; 156: 2149-2157 [PMID: 30873469 DOI: 10.1053/j.gastro.2019.02.046]

25 Kanwal F, Kramer J, Ash SM, Chayamapakul M, Cao Y, El-Serag HB. Risk of Hepatocellular Cancer in HCV Patients Treated With Direct-Antiviral Antiviral Agents. *Gastroenterology* 2017; 153: 996-1005.e1 [PMID: 28462197 DOI: 10.1053.j.gastro.2017.06.012]

26 Calvaruso V, Cabibbo G, Cacciola I, Petta S, Madonia S, Bellia A, Tinè A, D Stefanof M, Licata A, Giannitrapani L, Prestileo T, Mazzola G, Di Rosolini MA, Loracca L, Bertino G, Digiacomo A, Benanti F, Guarnieri L, Averna A, Iacobello C, Magro A, Scalisi I, Cartabellotta F, Savalli F, Barbara M, Davi A, Russello M, Scifo G, Squadrato G, Cammà C, Raimondo G, Craxi A, Di Marco V; Rete Sicilia Selezione Terapia–HCV (RESIST-HCV). Incidence of Hepatocellular Carcinoma in Patients With HCV-Associated Cirrhosis Treated With Direct-Antiviral Antiviral Agents. *Gastroenterology* 2018; 155: 411-421.e4 [PMID: 2965836 DOI: 10.1053.j.gastro.2018.04.008]
Compagnoni S et al. Pitfalls of direct antivirals for HCV

27 Tanaka Y, Ogawa E, Huang CF, Toyoda H, Jun DW, Tseng CH, HsuYC, Enomoto M, Takahashi H, Furusyo N, Yeh ML, Iio E, Yasuda S, Lam CP, Lee DH, Haga H, Yoon EL, Ahn SB, Wong G, Nakamuta M, Nomura H, Tsai PC, Jung JH, Song DS, Dang H, Maeda M, Henry L, Cheung R, Yuan MF, Ueno Y, Eguchi Y, Tamori A, Yu ML, Hayashi J, Nguye MH; REAL-C Investigators. HCC risk post-SVR with DAAs in East Asians: findings from the REAL-C cohort. *Hepatol Int* 2020; 14: 2203-2213 [PMID: 33277685 DOI: 10.1007/s12072-020-10155-2]

28 Kauwalla F, Kramer JR, Asch SM, Cao Y, Li L, El-Serag HB. Long-Term Risk of Hepatocellular Carcinoma in HCV Patients Treated With Direct Acting Antiviral Agents. *Hepatology* 2020; 71: 44-55 [PMID: 31222774 DOI: 10.1002/hep.30823]

29 Reig M, Mariño Z, Perello C, Iñarrarainegui M, Ribeiro A, Lenz S, Díaz A, Vilana R, Darnell A, Varela M, Sangro B, Calleja JL, Forns X, Bruix J. Unexpected high rate of early tumor recurrence in patients with HCV-related HCC undergoing interferon-free therapy. *J Hepatol* 2016; 65: 719-726 [PMID: 27084592 DOI: 10.1016/j.jhep.2016.04.008]

30 Waziry R, Hajarizadeh B, Grebely J, Amin J, Law M, Danta M, George J, Dore GJ. Hepatocellular carcinoma risk following direct-acting antiviral HCV therapy: A systematic review, meta-analyses, and meta-regression. *J Hepatol* 2017; 67: 1204-1212 [PMID: 28802876 DOI: 10.1016/j.jhep.2017.07.025]

31 Li DK, Ren Y, Fierer DS, Rutledge S, Shaikh OS, Lo Re V 3rd, Simon T, Abou-Samra AB, Chung RT, Butt AA. The short-term incidence of hepatocellular carcinoma is not increased after hepatitis C treatment with direct-acting antivirals: An ENRICHES study. *Hepatology* 2019; 67: 2244-2253 [PMID: 29205416 DOI: 10.1002/hep.29707]

32 Singal AG, Rich NE, Mehta N, Branch A, Pillai A, Hoteit M, Volk M, Odewole M, Scaglione S, Guy J, Said A, Feld JJ, John BV, Fenrette C, Mantry P, Rangnel AS, Olortungo O, Leise M, Jou HJ, Bhamidimarri KR, Kulik L, Tran T, Samant H, Dhanasekaran R, Duarte-Rojo A, Salgia R, Eswaran S, Jalal P, Flores A, Satapathy SK, Wong R, Huang A, Misra S, Schwartz M, Mitrani R, Nakka S, Noureddine W, Ho C, Konjeti VR, Diao A, Nelson K, Delarosa K, Rahman U, Mavaram M, Xie JJ, Murphy CC, Parikh ND. Direct-Antiviral Therapy Not Associated With Recurrence of Hepatocellular Carcinoma in a Multicenter North American Cohort Study. *Gastroenterology* 2020; 158: 1683-1692, e1 [PMID: 30660729 DOI: 10.1053/j.gastro.2019.01.027]

33 Cabibbo G, Celsa C, Calvaruso V, Petta S, Cacciola I, Cannavó MR, Madonia S, Rossi M, Magro R, Rini F, Distefano M, Larocca L, Prestileo T, Malizia G, Bertino G, Benanti F, Licata A, Scalsi I, Mazzola G, Di Rosolini MA, Alesso G, Averna A, Cartabellotta F, Alessi N, Guastella S, Russello M, Scifo G, Squadrato G, Raimondo G, Trevisani F, Craxi A, Di Marco V, Cannà C; Rete Sicilia Selezione Terapia – HCV (RESIST-HCV) and Italian Liver Cancer (ITA. LI.CA.) Group. Direct-acting antivirals after successful treatment of early hepatocellular carcinoma improve survival in HCV-cirrhotic patients. *J Hepatol* 2019; 71: 265-273 [PMID: 30959157 DOI: 10.1016/j.jhep.2019.03.027]

34 Singal AG, Rich NE, Mehta N, Branch AD, Pillai A, Hoteit M, Volk M, Odewole M, Scaglione S, Guy J, Said A, Feld JJ, John BV, Fenrette C, Mantry P, Rangnel AS, Olortungo O, Leise M, Jou HJ, Bhamidimarri KR, Kulik L, Tran T, Samant H, Dhanasekaran R, Duarte-Rojo A, Salgia R, Eswaran S, Jalal P, Flores A, Satapathy SK, Wong R, Huang A, Misra S, Schwartz M, Mitrani R, Nakka S, Noureddine W, Ho C, Konjeti VR, Diao A, Nelson K, Delarosa K, Rahman U, Mavaram M, Xie JJ, Murphy CC, Parikh ND. Direct-Antiviral Therapy Not Associated With Recurrence of Hepatocellular Carcinoma in a Multicenter North American Cohort Study. *Gastroenterology* 2020; 157: 1253-1263, e2 [PMID: 31374215 DOI: 10.1053/j.gastro.2019.07.040]

35 Cabibbo G, Petta S, Calvaruso V, Cacciola I, Cannavó MR, Madonia S, Distefano M, Larocca L, Prestileo T, Trinè F, Bertino G, Giammaritani L, Benanti F, Licata A, Scalsi I, Mazzola G, Cartabellotta F, Alessi N, Barbára M, Russello M, Scifo G, Squadrato G, Raimondo G, Trevisani F, Craxi A, Di Marco V, Cannà C; Rete Sicilia Selezione Terapia – HCV (RESIST-HCV). Is early recurrence of hepatocellular carcinoma in HCV cirrhotic patients affected by direct-acting antivirals? *Aliment Pharmacol Ther* 2017; 46: 688-695 [PMID: 28791711 DOI: 10.1111/apt.14256]

36 White DL, Ratziu V, El-Serag HB. Hepatitis C infection and risk of diabetes: a systematic review and meta-analysis. *J Hepatol* 2008; 49: 831-844 [PMID: 18849491 DOI: 10.1016/j.jhep.2008.08.006]

37 Desbois AC, Cacoub P. Diabetes mellitus, insulin resistance and hepatitis C virus infection: A contemporary review. *World J Gastroenterol* 2017; 23: 1697-1711 [PMID: 28321170 DOI: 10.3748/wjg.v23.i9.1697]

38 Chen Y, Ji H, Shao J, Jia Y, Bao Q, Zhu J, Zhang L, Shen Y. Different Hepatitis C Virus Infection Statuses Show a Significant Risk of Developing Type 2 Diabetes Mellitus: A Network Meta-Analysis. *Dig Dis Sci* 2020; 65: 1940-1950 [PMID: 31758432 DOI: 10.1007/s10620-019-05918-7]

39 Huang JF, Dai CY, Huang CF, Hsiao PJ, Hsiue MY, Lee LP, Lin ZY, Chen SC, Wang LY, Shin SJ, Chang WY, Chuang WL, Yu ML. Hepatitis C virus increases the association with type 2 diabetes mellitus in a hepatitis B and C endemic area: an epidemiological link with virological implication. *Am J Gastroenterol* 2007; 102: 1237-1243 [PMID: 17531012 DOI: 10.1111/j.1572-0241.2007.01181.x]

40 Visnegarwala F, Chen L, Raghavan S, Tedaldi E. Prevalence of diabetes mellitus and dyslipidemia among antiretroviral naive patients co-infected with hepatitis C virus (HCV) and HIV-1 compared to patients without co-infection. *J Infect* 2005; 50: 331-337 [PMID: 15845431 DOI: 10.1016/j.jinf.2004.06.001]

41 Huang YW, Yang SS, Fu SC, Wang TC, Hsu CK, Chen DS, Hu JT, Kao JH. Increased risk of cirrhosis and its decomposition in chronic hepatitis C patients with new-onset diabetes: a nationwide
cohort study. *Hepatology* 2014; 60: 807-814 [PMID: 24919583 DOI: 10.1002/hep.27212]

42 Hsu CS, Liu CH, Liu CJ, Hsu SJ, Chen CL, Huang JJ, Lai MY, Chen PJ, Chen DS, Kao JH. Association of metabolic profiles with hepatic fibrosis in chronic hepatitis C patients with genotype 1 or 2 infection. *J Gastroenterol Hepatol* 2010; 25: 970-977 [PMID: 20546452 DOI: 10.1111/j.1440-1746.2009.06186.x]

43 Elkrief L, Chouinard P, Bendersky N, Hajage D, Larroque B, Babany G, Kutala B, Francoz C, Boyer N, Moreau R, Durand F, Marcellin P, Rautou PE, Valla D. Diabetes mellitus is an independent prognostic factor for major liver-related outcomes in patients with cirrhosis and chronic hepatitis C. *Hepatology* 2014; 60: 823-831 [PMID: 24841704 DOI: 10.1002/hep.22728]

44 Huang YW, Wang TC, Yang SS, Lin SY, Fu SC, Hu JT, Liu CJ, Kao JH, Chen DS. Increased risk of hepatocellular carcinoma in chronic hepatitis C patients with new onset diabetes: a nationwide cohort study. *Aliment Pharmacol Ther* 2015; 42: 902-911 [PMID: 26211742 DOI: 10.1111/apt.13341]

45 Arase Y, Suzuki F, Suzuki Y, Akuta N, Kobayashi M, Kawamura Y, Yatsuji H, Szeaki H, Hosaka T, Hirakawa M, Ikeda K, Kumada H. Sustained virological response reduces incidence of onset of type 2 diabetes in chronic hepatitis C. *Hepatology* 2009; 49: 739-744 [PMID: 19127513 DOI: 10.1002/hep.22703]

46 Simó R, Lecuebe A, Genesca J, Esteban JJ, Hernández C. Sustained virological response correlates with reduction in the incidence of glucose abnormalities in patients with chronic hepatitis C virus infection. *Diabetes Care* 2006; 29: 2462-2466 [PMID: 17065685 DOI: 10.2337/dc06-0456]

47 Aghemo A, Prati GM, Rumi MG, Soffredini R, D’Ambrosio R, Orsi E, De Nicola S, Degasperi E, Grancini V, Colombo M. Sustained virological response prevents the development of insulin resistance in patients with chronic hepatitis C. *Hepatology* 2012; 56: 1681-1687 [PMID: 22691907 DOI: 10.1002/hep.25867]

48 Romero-Gómez M, Fernández-Rodríguez CM, Andrade RJ, Diago M, Alonso S, Planas R, Solá R, Pons JA, Salmerón J, Barcena R, Perez R, Carmona I, Durán S. Effect of sustained virological response to treatment on the incidence of abnormal glucose values in chronic hepatitis C. *J Hepatol* 2008; 48: 721-727 [PMID: 18308416 DOI: 10.1016/j.jhep.2007.11.022]

49 Alsebaey A, Elhelbawy M, Abdel-Razek W, Hashim M, Elshenawy H, Waked I. HCV treatment with direct acting antivirals improves the insulin sensitivity. *Expert Rev Anti Infect Ther* 2019; 17: 749-754 [PMID: 31393188 DOI: 10.1080/14787210.2019.1653184]

50 Ribaldone DG, Sacco M, Saracco GM. The Effect of Viral Clearance Achieved by Direct-Acting Antiviral Agents on Hepatitis C Virus Positive Patients with Type 2 Diabetes Mellitus: A Word of Caution after the Initial Enthusiasm. *J Clin Med* 2020; 9 [PMID: 32092802 DOI: 10.3390/jcm9020563]

51 Carnovale C, Pozzi M, Dassano A, D’Addio F, Gentili M, Magni C, Clementi E, Radice S, Fiorina P. The impact of a successful treatment of hepatitis C virus on glyco-metabolic control in diabetic patients: a systematic review and meta-analysis. *Acta Diabetol* 2019; 56: 341-354 [PMID: 30478781 DOI: 10.1007/s00592-018-1257-1]

52 Hum J, Jou JH, Green PK, Berry K, Lundblad J, Hettinger BD, Chang M, Ioannou GN. Improvement in Glycemic Control of Type 2 Diabetes After Successful Treatment of Hepatitis C Virus. *Diabetes Care* 2017; 40: 1173-1180 [PMID: 26959309 DOI: 10.2337/dc17-0485]

53 Ciancio A, Bosito R, Bo S, Pellegrini M, Sacco M, Vogliotti E, Fassio G, Bianco Mauthe Degerfeld AGF, Gallo M, Giordannino C, Terzi di Bergamo L, Ribaldone D, Bugianesi E, Smedile A, Rizzato M, Saracco GM. Significant improvement of glycemic control in diabetic patients with HCV infection responding to direct-acting antiviral agents. *J Med Virol* 2018; 90: 320-327 [PMID: 28960353 DOI: 10.1002/jmv.24954]

54 Adinolfi LE, Nevolà R, Guerrera B, D’Alterio G, Mannone A, Giordano M, Rinaldi L. Hepatitis C virus infection by direct-acting antiviral treatments and impact on insulin resistance in chronic hepatitis C patients. *J Gastroenterol Hepatol* 2018; 33: 1379-1382 [PMID: 29228501 DOI: 10.1111/jgh.14067]

55 Weidner P, Boettcher D, Zimmerer T, Burgermeister E, Teufel A, Antoni C. Impact of direct acting antiviral (DAAs) treatment on glucose metabolism and reduction of pre-diabetes in patients with chronic hepatitis C. *J Gastrointestin Liver Dis* 2018; 27: 281-289 [PMID: 30240472 DOI: 10.15403/jglid.2014.1121.273.dae]

56 Hsu YC, Lin JT, Ho HJ, Kao YH, Huang YT, Hsiao NW, Wu MS, Liu YY, Wu CY. Antiviral treatment for hepatitis C virus infection is associated with improved renal and cardiovascular outcomes in diabetic patients. *Hepatology* 2014; 59: 1293-1302 [PMID: 24122848 DOI: 10.1002/hep.26982]

57 Li J, Gordon SC, Rupp LB, Zhang T, Trueau S, Holmberg SD, Moorman AC, Spradling PR, Teshale EH, Boscarino JA, Schmidt MA, Daida YG, Lu M; ChEsCS Investigators. Sustained virological response to hepatitis C treatment decreases the incidence of complications associated with type 2 diabetes. *Aliment Pharmacol Ther* 2019; 49: 599-608 [PMID: 30650468 DOI: 10.1111/apt.15102]

58 Summary Safety Review - Direct-acting antivirals (DAAs) - Health Canada. 2020 Feb 17 [cited 27 December 2020]. In: Government of Canada [Internet]. Available from: https://hpr-rcps.hrs.ca/reg-content/summary-safety-review-detail.php?linkID=SSR00234

59 Negro F. Natural History of Hepatic and Extrahepatic Hepatitis C Virus Diseases and Impact of Interferon-Free HCV Therapy. *Cold Spring Harb Perspect Med* 2020; 10: a036921 [PMID: 31636094 DOI: 10.1101/cshperspect.a036921]
Compagnoni S et al. Pitfalls of direct antivirals for HCV

60 Boddi M, Abbate R, Chellini B, Giusti B, Gianinni C, Pratesi G, Rossi L, Pratesi C, Gensini GF, Paperetti L, Zignego AL. Hepatitis C virus RNA localization in human carotid plaques. *J Clin Virol* 2010; 47: 72-75 [PMID: 19896417 DOI: 10.1016/j.jcv.2009.10.005]

61 Petta S, Amato M, Cabibi D, Campà C, Di Marco V, Giordano C, Galluzzo A, Craxi A. Visceral adiposity index is associated with histological findings and high viral load in patients with chronic hepatitis C due to genotype 1. *Hepatology* 2010; 52: 1543-1552 [PMID: 20799355 DOI: 10.1002/hep.23859]

62 Rehermann B. Pathogenesis of chronic viral hepatitis: differential roles of T cells and NK cells. *Nat Med* 2013; 19: 859-868 [PMID: 23836236 DOI: 10.1038/nm.3251]

63 Petteni JM, Minello A, Jooste V, Bour JB, Galland F, Duviillard L, Verges B, Olsson NO, Gambert P, Hillon P. Decreased plasma adiponectin concentrations are closely related to steatosis in hepatitis C virus-infected patients. *J Clin Endocrinol Metab* 2005; 90: 2240-2243 [PMID: 15644404 DOI: 10.1210/jc.2004-1266]

64 Cua IH, Hui JM, Bandara P, Kench JG, Farrell GC, McCaughan GW, George J. Insulin resistance and liver injury in hepatitis C is not associated with virus-specific changes in adipokines. *Hepatology* 2007; 46: 66-73 [PMID: 17596870 DOI: 10.1002/hep.21703]

65 González-Reimers E, Quintero-Platt G, Martín-González C, Pérez-Hernández O, Romero-Acevedo L, Santolaria-Fernández F. Thrombin activation and liver inflammation in advanced hepatitis C virus infection. *World J Gastroenterol* 2016; 22: 4427-4437 [PMID: 27182154 DOI: 10.3748/wjg.v22.i18.4427]

66 Butt AA, Xiaoqiang W, Budoff M, Leaf D, Kuller LH. Justice AC. Hepatitis C virus infection and the risk of coronary disease. *Clin Infect Dis* 2009; 49: 225-232 [PMID: 19508160 DOI: 10.1086/593711]

67 Howard G, Sharrett AR, Heiss G, Evans GW, Chambless LE, Riley WA, Burke GL. Carotid artery intimal-medial thickness distribution in general populations as evaluated by B-mode ultrasound. ARIC Investigators. *Stroke* 1993; 24: 1297-1304 [PMID: 8362421 DOI: 10.1161/01.str.24.9.1297]

68 Chambless LE, Heiss G, Folsom AR, Rosamond W, Szkelo M, Sharrett AR, Clegg LX. Association of coronary heart disease incidence with carotid arterial wall thickness and major risk factors: the Atherosclerosis Risk in Communities (ARIC) Study, 1987-1993. *Am J Epidemiol* 1997; 146: 483-494 [PMID: 9290509 DOI: 10.1093/oxfordjournals.aje.a009302]

69 Butt AA, Yan P, Shuaib A, Abou-Samra AB, Shaikh OS, Freiberg MS. Direct-Acting Antiviral Therapy for HCV Infection is Associated With a Reduced Risk of Cardiovascular Disease Events. *Gastroenterology* 2019; 156: 987-996. e8 [PMID: 30445009 DOI: 10.1053.j.gastro.2018.11.022]

70 Magro B, Calvaruso V, Petta S, Cacciola I, Cabibbo G, Cartabellotta F, Di Rosolini A, Davi A, Cannavò M, Russello M, Di Stefano M, Sció G, Di Lorenzo F, Prestileo T, LaRocca L, Montaneri A, Fiduli G, Di Greggio A, Cannizzarro M, Madonia S, Licata A, Malizia G, Alaimo G, Bertino G, Cacopardo B, Iacobello C, Averna A, Guarnieri L, Scalisi I, Mazzola G, Mondello L, Portelli V, Squadrino G, Cammà C, Raimondo G, Craxi A, Di Marco V. Liver and cardiovascular mortality after DAAS: data from the RESIST-HCV cohort. *Dig Liver Dis* 2019; 51: e75-e76 [DOI: 10.1016/j.dld.2019.05.003]

71 Calvaruso V, Craxi A. Hepatic benefits of HCV cure. *J Hepatol* 2020; 73: 1548-1556 [PMID: 32777323 DOI: 10.1016/j.jhep.2020.08.006]

72 Calvaruso V, Petta S, Cacciola I, Cabibbo G, Cartabellotta F, Di Rosolini A, Davi A, Cannavò M, Russello M, Distefano M, Sció G, Di Lorenzo F, Prestileo T, LaRocca L, Montaneri A, Fiduli G, Di Greggio A, Cannizzarro M, Madonia S, Licata A, Malizia G, Alaimo G, Bertino G, Cacopardo B, Iacobello C, Averna A, Guarnieri L, Scalisi I, Mazzola G, Mondello L, Portelli V, Squadrino G, Cammà C, Raimondo G, Craxi A, Di Marco V. Disease outcomes after DAAS-induced SVR: data from the resist-HCV cohort. *J Hepatol* 2018; 68: S83 [DOI: 10.1016/S0168-8278(18)30385-4]

73 Cacoub P, Nahon P, Layeux L, Blaise L, Desbois AC, Bourcier V, Cagnet M, Marcellin P, Guyader D, Pol S, Larrey D, De Lédinghen V, Ouzan D, Zoulim F, Roulot D, Tran A, Bronswick JP, Zarzki JP, Riachi G, Calès P, Péron JM, Alric L, Bourlière M, Mathurin P, Blanc JF, Abergel A, Serfâty L, Mallat A, Grangé JD, Attali P, Bacq Y, Wartelle C, Dao T, Thabut D, Pilette C, Silvain C, Christidis C, Capron D, Thieffin G, Zucman D, Di Martino V, Baginis CI, Ziol M, Sutton A, Letouze E, Roudot-Thoraval F, Audureau E; ANRS CO12 CirVir group. Prognostic value of viral eradication for major adverse cardiovascular events in hepatitis C cirrhotic patients. *Am Heart J* 2018; 198: 4-17 [PMID: 29653647 DOI: 10.1016/j.ahj.2017.10.024]

74 Pothoff A, Berg T, Wedemeyer H; HEP-NET/B C Coinfection Study Group. Late hepatitis B virus relapse in patients co-infected with hepatitis B virus and hepatitis C virus after antiviral treatment with pegylated interferon-a2b and ribavirin. *Scand J Gastroenterol* 2009; 44: 1487-1490 [PMID: 19900555 DOI: 10.3109/03003655.2009.3329585]

75 Wang C, Ji D, Chen J, Shao Q, Li B, Liu J, Wu V, Wong A, Wang Y, Zhang X, Lu L, Wong C, Tsang S, Zhang Z, Sun J, Hou J, Chen G, Lau G. Hepatitis due to Reactivation of Hepatitis B Virus in Endemic Areas Among Patients With Hepatitis C Treated With Direct-Acting Antiviral Agents. *Clin Gastroenterol Hepatol* 2017; 15: 132-136 [PMID: 27392759 DOI: 10.1016/j.cgh.2016.06.023]

76 Bersoff-Matcha SJ, Cao K, Jason M, Aja A, Jones SC, Meyer T, Brinker A. Hepatitis B Virus Reactivation Associated With Direct-Acting Antiviral Therapy for Chronic Hepatitis C Virus: A Review of Cases Reported to the U.S. Food and Drug Administration Adverse Event Reporting System. *Ann Intern Med* 2017; 166: 792-798 [PMID: 28437794 DOI: 10.7326/M17-0377]

77 Pockros PJ. Black Box Warning for Possible HBV Reactivation During DAA Therapy for Chronic HCV Infection. *Gastroenterol Hepatol (N Y)* 2017; 13: 536-540 [PMID: 29038644]
78 Madonia S, Orlando E, Madonia G, Cannizzaro M. HCV/HBV coinfection: The dark side of DAAs treatment? *Liver Int* 2017; 37: 1086-1087 [PMID: 27966812 DOI: 10.1111/Liv.13342]

79 Ozaras R, Mete B, Tabak F. Occult Hepatitis B and Risk of Reactivation After Hepatitis C Treatment With Direct-Acting Antivirals. *Clin Gastroenterol Hepatol* 2017; 15: 605 [PMID: 27923721 DOI: 10.1016/j.cgh.2016.11.030]

80 Liu CJ, Chuang WL, Sheen IS, Wang HY, Chen CY, Tseng KC, Chang TT, Massetto B, Yang JC, Yun C, Knox SJ, Osimasi A, Camus G, Jiang D, Brainard DM, McHutchison JG, Hu TH, Hsu YC, Lo GH, Chu CJ, Chen JJ, Peng CY, Chien RN, Chen PJ. Efficacy of Ledipasvir and Sofosbuvir Treatment of HCV Infection in Patients Coinfected With HBV. *Gastroenterology* 2018; 154: 989-997 [PMID: 29174546 DOI: 10.1053/j.gastro.2017.11.011]
